US794392A
(en)
*
|
1904-01-29 |
1905-07-11 |
Nat Tube Co |
Bending-roll.
|
US4482571A
(en)
|
1982-06-21 |
1984-11-13 |
University Of Pittsburgh |
Sickle cell anemia treatment and compound
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
JPH07107047B2
(ja)
|
1985-10-17 |
1995-11-15 |
アイ・シ−・アイ・アメリカス・インコ−ポレイテツド |
新規ヘテロ環式化合物及びその製法
|
US4964895A
(en)
|
1987-06-08 |
1990-10-23 |
Monsanto Company |
Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides
|
US4997815A
(en)
*
|
1988-11-01 |
1991-03-05 |
Children's Hospital Medical Center Of Northern California |
Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
|
CA2046628A1
(en)
*
|
1989-02-08 |
1990-08-09 |
Dee W. Brooks |
4-hydroxythiazoles as 5-lipoxygenase inhibitors
|
US5216004A
(en)
*
|
1990-09-13 |
1993-06-01 |
Children's Hospital Medical Center Of North California |
Method for preventing malaria
|
US5656644A
(en)
|
1994-07-20 |
1997-08-12 |
Smithkline Beecham Corporation |
Pyridyl imidazoles
|
US5439939A
(en)
|
1992-03-17 |
1995-08-08 |
Children's Hospital Medical Center Of Northern California |
Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
|
WO1995011699A1
(en)
*
|
1993-10-29 |
1995-05-04 |
The Trustees Of Boston University |
Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
|
AU679818B2
(en)
|
1993-11-10 |
1997-07-10 |
Sloan-Kettering Institute For Cancer Research |
Butyric ester cyto-differentiating agents
|
US5569675A
(en)
|
1994-03-07 |
1996-10-29 |
Bar Ilan University |
Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
|
US6071923A
(en)
*
|
1994-09-16 |
2000-06-06 |
Bar-Ilan University |
Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
US6040342A
(en)
*
|
1994-09-16 |
2000-03-21 |
Bar-Ilan University |
Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
|
US5789434A
(en)
|
1994-11-15 |
1998-08-04 |
Bayer Corporation |
Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
|
US6011000A
(en)
*
|
1995-03-03 |
2000-01-04 |
Perrine; Susan P. |
Compositions for the treatment of blood disorders
|
US5700826A
(en)
|
1995-06-07 |
1997-12-23 |
Ontogen Corporation |
1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
|
JP3964478B2
(ja)
|
1995-06-30 |
2007-08-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
|
WO1997011366A1
(en)
|
1995-09-20 |
1997-03-27 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
US6110697A
(en)
|
1995-09-20 |
2000-08-29 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
US5922837A
(en)
|
1995-09-20 |
1999-07-13 |
Merck & Co., Inc. |
Antiprotozoal cyclic tetrapeptides
|
US20030219832A1
(en)
|
1996-03-11 |
2003-11-27 |
Klein Elliott S. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
WO1997047307A1
(en)
|
1996-06-14 |
1997-12-18 |
The Uab Research Foundation |
Use of histone deacetylase inhibitors to activate transgene expression
|
EP0927033A1
(en)
|
1996-07-02 |
1999-07-07 |
Bar-Ilan University |
Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
US6197743B1
(en)
*
|
1996-07-26 |
2001-03-06 |
The Trustees Of Boston University |
Compositions and methods for the treatment of viral disorders
|
US5939456A
(en)
|
1996-07-26 |
1999-08-17 |
Perrine; Susan P. |
Pulsed administration of compositions for the treatment of blood disorders
|
EP0827742A1
(en)
|
1996-09-04 |
1998-03-11 |
Vrije Universiteit Brussel |
Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
|
US6068987A
(en)
*
|
1996-09-20 |
2000-05-30 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
US6794392B1
(en)
|
1996-09-30 |
2004-09-21 |
Schering Aktiengesellschaft |
Cell differentiation inducer
|
US6174905B1
(en)
|
1996-09-30 |
2001-01-16 |
Mitsui Chemicals, Inc. |
Cell differentiation inducer
|
PL334250A1
(en)
|
1996-12-23 |
2000-02-14 |
Du Pont Pharm Co |
Nitrogen containing hetero-aromatic compounds and inhibitors of xa factor
|
US6235474B1
(en)
*
|
1996-12-30 |
2001-05-22 |
The Johns Hopkins University |
Methods and kits for diagnosing and determination of the predisposition for diseases
|
US6130248A
(en)
|
1996-12-30 |
2000-10-10 |
Bar-Ilan University |
Tricarboxylic acid-containing oxyalkyl esters and uses thereof
|
AU5617398A
(en)
|
1996-12-30 |
1998-07-31 |
Beacon Laboratories L.L.C. |
Tricarboxylic acid-containing oxyalkyl esters and uses thereof
|
US7062219B2
(en)
|
1997-01-31 |
2006-06-13 |
Odyssey Thera Inc. |
Protein fragment complementation assays for high-throughput and high-content screening
|
US6030961A
(en)
*
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
US6043389A
(en)
*
|
1997-03-11 |
2000-03-28 |
Mor Research Applications, Ltd. |
Hydroxy and ether-containing oxyalkylene esters and uses thereof
|
US6110955A
(en)
|
1997-03-11 |
2000-08-29 |
Beacon Laboratories, Inc. |
Metabolically stabilized oxyalkylene esters and uses thereof
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
US5939455A
(en)
|
1997-03-11 |
1999-08-17 |
Beacon Laboratories, Inc. |
Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
|
US6110970A
(en)
|
1997-03-11 |
2000-08-29 |
Beacon Laboratories, Inc. |
Nitrogen-containing oxyalkylene esters and uses thereof
|
US6387673B1
(en)
*
|
1997-05-01 |
2002-05-14 |
The Salk Institute For Biological Studies |
Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
AUPO721997A0
(en)
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
AUPO864097A0
(en)
*
|
1997-08-19 |
1997-09-11 |
Peplin Pty Ltd |
Anti-cancer compounds
|
CA2302451A1
(en)
|
1997-09-02 |
1999-03-11 |
Japan Energy Corporation |
Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
|
CA2308377A1
(en)
|
1997-11-10 |
1999-05-20 |
The Salk Institute For Biological Studies |
Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
|
US6884597B1
(en)
*
|
1998-01-20 |
2005-04-26 |
Medical & Biological Laboratories, Co., Ltd. |
Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
|
US6262116B1
(en)
|
1998-01-23 |
2001-07-17 |
Sloan-Kettering Institute For Cancer Research |
Transcription therapy for cancers
|
WO1999040883A2
(en)
|
1998-02-11 |
1999-08-19 |
Faller Douglas V |
Compositions and methods for the treatment of cystic fibrosis
|
US6287843B1
(en)
|
1998-04-03 |
2001-09-11 |
Pioneer Hi-Bred International, Inc. |
Maize histone deacetylases and their use
|
US6288063B1
(en)
|
1998-05-27 |
2001-09-11 |
Bayer Corporation |
Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
|
US20030236204A1
(en)
*
|
2002-06-14 |
2003-12-25 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 2 expression
|
AUPP505798A0
(en)
|
1998-08-04 |
1998-08-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel compound fr225497 substance
|
JP2002523029A
(ja)
|
1998-08-21 |
2002-07-30 |
スミスクライン ビーチャム コーポレーション |
ヒトヒストンデアセチラーゼ遺伝子hd4
|
DE19842506A1
(de)
|
1998-09-17 |
2000-03-23 |
Volkswagen Ag |
Verfahren und Vorrichtung zur Überwachung von Signalen bei vernetzten Systemen
|
EP1123309A2
(en)
|
1998-10-13 |
2001-08-16 |
Fujisawa Pharmaceutical Co., Ltd. |
Cyclic tetrapeptides and their use as histone deacetylase inhibitor
|
JP2002527101A
(ja)
|
1998-10-16 |
2002-08-27 |
ノバルティス アクチエンゲゼルシャフト |
ヒストンデアセチラーゼ阻害剤による造血幹細胞への遺伝子形質導入の改良及び自己再生の促進
|
EP1137771A2
(en)
*
|
1998-11-10 |
2001-10-04 |
The Board Of Regents, The University Of Texas System |
Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
|
US6287790B1
(en)
|
1998-11-30 |
2001-09-11 |
The Regents Of The University Of California |
Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
|
AU3316600A
(en)
*
|
1999-02-22 |
2000-09-21 |
Torben F. Orntoft |
Gene expression in bladder tumors
|
JP4269041B2
(ja)
|
1999-03-02 |
2009-05-27 |
国立大学法人九州工業大学 |
新規な環状テトラペプチド誘導体とその医薬用途
|
DE60028554T2
(de)
|
1999-03-23 |
2007-05-16 |
Chugai Seiyaku K.K. |
Verfahren zum screenen nach gegen krebs gerichteten medikamenten
|
US6518012B1
(en)
*
|
1999-04-02 |
2003-02-11 |
Health Research, Inc. |
Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
|
EP1169317B1
(en)
|
1999-04-09 |
2003-01-15 |
SmithKline Beecham Corporation |
Triarylimidazoles
|
US20030078216A1
(en)
|
1999-05-03 |
2003-04-24 |
Macleod A. Robert |
Inhibition of histone deactylase
|
CA2366408A1
(en)
|
1999-05-03 |
2000-11-30 |
Methylgene, Inc. |
Inhibition of histone deacetylase
|
US20030078369A1
(en)
|
1999-07-23 |
2003-04-24 |
Meinke Peter T. |
Apicidin-derived cyclic tetrapeptides
|
WO2001007042A1
(en)
|
1999-07-23 |
2001-02-01 |
Merck & Co., Inc. |
Apicidin-derived cyclic tetrapeptides
|
WO2001014581A2
(en)
|
1999-08-20 |
2001-03-01 |
Board Of Regents, The University Of Texas System |
Hdac4 and hdac5 in the regulation of cardiac gene expression
|
JP2001081031A
(ja)
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
AU7108400A
(en)
|
1999-09-03 |
2001-04-10 |
Salk Institute For Biological Studies, The |
Modulation of gene expression by modulating histone acetylation
|
BR0014254A
(pt)
|
1999-09-08 |
2002-08-27 |
Sloan Kettering Inst Cancer |
Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
|
EP1212357B1
(en)
*
|
1999-09-08 |
2007-05-02 |
Sloan-Kettering Institute For Cancer Research |
Crystal structure of a deacetylase and inhibitors thereof
|
JP2003511054A
(ja)
|
1999-10-08 |
2003-03-25 |
メルク エンド カムパニー インコーポレーテッド |
抗原虫ヒストンアセチルトランスフェラーゼインヒビター
|
PT1233958E
(pt)
|
1999-11-23 |
2011-09-20 |
Methylgene Inc |
Inibidores de histona desacetilase
|
JP2001149081A
(ja)
|
1999-11-29 |
2001-06-05 |
Cyclex Co Ltd |
脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
DE60033453T2
(de)
|
1999-12-08 |
2007-11-29 |
Cyclacel Pharmaceuticals Inc. |
Verwendung von Depsipeptide und deren Analoge als Immunosuppressiva zur Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Allergien und hyperproliferativer Hautkrankheiten
|
US6875598B1
(en)
*
|
1999-12-08 |
2005-04-05 |
Applera Corporation |
Histone deacetylase-8 proteins, nuclei acids, and methods for use
|
EP1246905B1
(en)
|
1999-12-08 |
2006-03-15 |
Axys Pharmaceuticals, Inc. |
Histone deacetylase-8 proteins, nucleic acids, and methods of use
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
US7452664B2
(en)
|
1999-12-15 |
2008-11-18 |
Massachusetts Institute Of Technology |
Methods for identifying agents which alter histone protein acetylation
|
US6544957B2
(en)
|
2000-01-04 |
2003-04-08 |
The Johns Hopkins University |
Methods and reagents for facilitating transcription
|
AU5077401A
(en)
*
|
2000-02-08 |
2001-08-20 |
Sangamo Biosciences Inc |
Cells for drug discovery
|
ATE311366T1
(de)
*
|
2000-02-29 |
2005-12-15 |
Millennium Pharm Inc |
Benzamide und ähnliche inhibitoren vom faktor xa
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
GB0005199D0
(en)
|
2000-03-04 |
2000-04-26 |
Imp College Innovations Ltd |
Modulation of histone deacetylase
|
WO2001072784A2
(en)
|
2000-03-24 |
2001-10-04 |
Filgen Biosciences, Inc. |
Peptides binding to non-acetylated h3 and h4 histones for cancer therapy
|
WO2003006652A2
(en)
|
2000-03-24 |
2003-01-23 |
Methylgene, Inc. |
Inhibition of specific histone deacetylase isoforms
|
AU2001248701A1
(en)
|
2000-03-24 |
2001-10-03 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
US20020137162A1
(en)
|
2000-03-24 |
2002-09-26 |
Zuomei Li |
Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
|
GB0007217D0
(en)
|
2000-03-24 |
2000-05-17 |
Europ I Of Oncology |
Materials and methods relating to the treatment of leukaemias
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
US6458589B1
(en)
*
|
2000-04-27 |
2002-10-01 |
Geron Corporation |
Hepatocyte lineage cells derived from pluripotent stem cells
|
EP1170008A1
(en)
*
|
2000-07-07 |
2002-01-09 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Valproic acid and derivatives thereof as histone deacetylase inhibitors
|
DE60137932D1
(de)
|
2000-07-17 |
2009-04-23 |
Astellas Pharma Inc |
Reduziertes fk228 und seine verwendung
|
AU2001277105A1
(en)
|
2000-07-21 |
2002-02-05 |
Millennium Pharmaceuticals, Inc. |
47508, a novel human histone deacetylase family member and uses thereof
|
EP1310485A4
(en)
|
2000-07-28 |
2005-07-20 |
Sumitomo Pharma |
PYRROLE DERIVATIVES
|
US6673587B1
(en)
*
|
2000-08-11 |
2004-01-06 |
The Salk Institute For Biological Studies |
Histone deacetylase, and uses therefor
|
EP1182263A1
(en)
|
2000-08-11 |
2002-02-27 |
Evotec OAI AG |
Process for detecting threonine/serine kinase activity
|
WO2002015921A2
(en)
|
2000-08-18 |
2002-02-28 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
PE20020354A1
(es)
*
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
US20050004007A1
(en)
|
2000-09-12 |
2005-01-06 |
Steven Grant |
Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
|
US6538030B2
(en)
|
2000-09-20 |
2003-03-25 |
Yih-Lin Chung |
Treating radiation fibrosis
|
EP2292593A3
(en)
*
|
2000-09-29 |
2011-05-25 |
TopoTarget UK Limited |
Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
|
GB0023983D0
(en)
|
2000-09-29 |
2000-11-15 |
Prolifix Ltd |
Therapeutic compounds
|
WO2002026696A1
(en)
*
|
2000-09-29 |
2002-04-04 |
Prolifix Limited |
Carbamic acid compounds comprising an amide linkage as hdac inhibitors
|
AU2002215018A1
(en)
|
2000-10-13 |
2002-04-22 |
Bayer Aktiengesellschaft |
Human histone deacetylase gene
|
DE10053474A1
(de)
|
2000-10-24 |
2002-05-02 |
Schering Ag |
Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
|
US20020103192A1
(en)
|
2000-10-26 |
2002-08-01 |
Curtin Michael L. |
Inhibitors of histone deacetylase
|
AU2002212350A1
(en)
*
|
2000-10-31 |
2002-05-15 |
Bayer Aktiengesellschaft |
Regulation of human histone deacetylase
|
US7439359B2
(en)
|
2000-11-02 |
2008-10-21 |
Sloan-Kettering Institute For Cancer Research |
Small molecule compositions for binding to hsp90
|
WO2002055017A2
(en)
|
2000-11-21 |
2002-07-18 |
Wake Forest University |
Method of treating autoimmune diseases
|
DE10061162A1
(de)
|
2000-11-30 |
2002-07-11 |
Schering Ag |
Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
|
AR035659A1
(es)
|
2000-12-07 |
2004-06-23 |
Hoffmann La Roche |
Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
|
US6376508B1
(en)
*
|
2000-12-13 |
2002-04-23 |
Academia Sinica |
Treatments for spinal muscular atrophy
|
US20040005574A1
(en)
*
|
2002-07-08 |
2004-01-08 |
Leonard Guarente |
SIR2 activity
|
US20030154032A1
(en)
|
2000-12-15 |
2003-08-14 |
Pittman Debra D. |
Methods and compositions for diagnosing and treating rheumatoid arthritis
|
US20050171042A1
(en)
|
2000-12-19 |
2005-08-04 |
Monia Brett P. |
Compositions and their uses directed to binding proteins
|
US20040204373A1
(en)
|
2000-12-19 |
2004-10-14 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase I expression
|
US6693132B2
(en)
|
2000-12-21 |
2004-02-17 |
Beacon Laboratories, Inc. |
Methods for using alkanoyloxymethyl esters
|
WO2002050285A2
(en)
|
2000-12-20 |
2002-06-27 |
Novartis Ag |
Histone deacetylase-related gene and protein
|
US6720445B2
(en)
*
|
2000-12-21 |
2004-04-13 |
Beacon Laboratories, Inc. |
Acetyloxymethyl esters and methods for using the same
|
US6562995B1
(en)
|
2000-12-21 |
2003-05-13 |
Beacon Laboratories, Inc. |
Delta dicarbonyl compounds and methods for using the same
|
KR100456047B1
(ko)
*
|
2000-12-22 |
2004-11-08 |
이인원 |
애피시딘 유도체, 이의 합성방법 및 이를 포함하는 항암제조성물
|
AR035513A1
(es)
|
2000-12-23 |
2004-06-02 |
Hoffmann La Roche |
Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
|
WO2002055688A2
(en)
|
2001-01-10 |
2002-07-18 |
Us Gov Health & Human Serv |
Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
|
US20030148970A1
(en)
|
2001-01-12 |
2003-08-07 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-4
|
WO2002069947A2
(en)
|
2001-01-12 |
2002-09-12 |
Methylgene, Inc. |
Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer
|
US20030152557A1
(en)
|
2001-01-12 |
2003-08-14 |
Besterman Jeffrey M. |
Methods for inhibiting histone deacetylase-4
|
US6756200B2
(en)
*
|
2001-01-26 |
2004-06-29 |
The Johns Hopkins University School Of Medicine |
Aberrantly methylated genes as markers of breast malignancy
|
AR035417A1
(es)
|
2001-01-27 |
2004-05-26 |
Hoffmann La Roche |
Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
|
WO2002060430A1
(en)
|
2001-02-01 |
2002-08-08 |
Cornell Research Foundation, Inc. |
Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
|
EP1499714A2
(en)
*
|
2001-02-05 |
2005-01-26 |
Bayer HealthCare AG |
Regulation of human histone acetyltransferase
|
US20020177594A1
(en)
|
2001-03-14 |
2002-11-28 |
Curtin Michael L. |
Inhibitors of histone deacetylase
|
CA2442366C
(en)
|
2001-03-27 |
2012-09-25 |
Circagen Pharmaceutical, Llc |
Histone deacetylase inhibitors
|
US6495719B2
(en)
|
2001-03-27 |
2002-12-17 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
US8026280B2
(en)
|
2001-03-27 |
2011-09-27 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
US7057057B2
(en)
*
|
2002-05-22 |
2006-06-06 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
|
US7312247B2
(en)
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
DE60113645T2
(de)
|
2001-04-10 |
2006-07-06 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Verwendung von Histonedeacetylasehemmern zur Behandlung von Papillomaviren assoziierte Krankheiten
|
AR035455A1
(es)
*
|
2001-04-23 |
2004-05-26 |
Hoffmann La Roche |
Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
EP1390491B1
(en)
|
2001-05-02 |
2008-07-16 |
The Regents of the University of California |
Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors
|
US7244853B2
(en)
*
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
US20030187027A1
(en)
|
2001-05-09 |
2003-10-02 |
Schreiber Stuart L. |
Dioxanes and uses thereof
|
US7199227B2
(en)
|
2001-06-14 |
2007-04-03 |
Bristol-Myers Squibb Company |
Polynucleotides encoding human histone deacetylase HDAC9c
|
EP1409661A4
(en)
|
2001-06-14 |
2006-02-01 |
Sloan Kettering Inst Cancer |
HDAC9 POLYPEPTIDES AND POLYNUCLEOTIDES AND USES THEREOF
|
US6784173B2
(en)
*
|
2001-06-15 |
2004-08-31 |
Hoffmann-La Roche Inc. |
Aromatic dicarboxylic acid derivatives
|
US7241743B2
(en)
|
2001-06-15 |
2007-07-10 |
The Trustees Of Columbia University In The City Of New York |
Sir2α-based therapeutic and prophylactic methods
|
AU2002315229A1
(en)
|
2001-06-19 |
2003-01-02 |
The Regents Of The University Of California |
Histone deacetylase and methods of use thereof
|
WO2003000715A1
(en)
|
2001-06-22 |
2003-01-03 |
Ceres, Inc. |
Chimeric histone acetyltransferase polypeptides
|
US20040186274A1
(en)
|
2001-07-03 |
2004-09-23 |
Allis C. David |
Methylation of histone h4 at arginine 3
|
WO2003014340A2
(en)
|
2001-08-03 |
2003-02-20 |
Novartis Ag |
Human histone deacetylase-related gene and protein hdac10
|
US20040266718A1
(en)
|
2001-08-06 |
2004-12-30 |
Zuomei Li |
Inhibition of specific histone deacetylase isoforms
|
ITMI20011733A1
(it)
|
2001-08-07 |
2003-02-07 |
Italfarmaco Spa |
Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
|
AR034897A1
(es)
|
2001-08-07 |
2004-03-24 |
Hoffmann La Roche |
Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
|
US8470783B2
(en)
|
2001-08-21 |
2013-06-25 |
Astellas Pharma Inc. |
Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
|
WO2003017763A1
(en)
|
2001-08-24 |
2003-03-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1291015A1
(en)
|
2001-09-10 |
2003-03-12 |
Lunamed AG |
Dosage forms having prolonged active ingredient release
|
US7868204B2
(en)
|
2001-09-14 |
2011-01-11 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
US6897220B2
(en)
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
MXPA04002397A
(es)
*
|
2001-09-14 |
2004-12-02 |
Methylgene Inc |
Inhibidores de histona deacetilasa.
|
EP1293205A1
(en)
*
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
DE10148618B4
(de)
|
2001-09-25 |
2007-05-03 |
Schering Ag |
Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
|
US6706686B2
(en)
*
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
GB0123664D0
(en)
|
2001-10-02 |
2001-11-21 |
Inst Of Cancer Res The |
Histone deacetylase 9
|
ATE517624T1
(de)
|
2001-10-16 |
2011-08-15 |
Sloan Kettering Inst Cancer |
Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
|
US7229963B2
(en)
|
2001-10-18 |
2007-06-12 |
United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health |
Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
|
US7402603B2
(en)
|
2001-11-06 |
2008-07-22 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
JP2005528331A
(ja)
|
2001-11-21 |
2005-09-22 |
イェシバ・ユニバーシティ |
Sir2産物および活性
|
US7514406B2
(en)
*
|
2001-11-27 |
2009-04-07 |
Fred Hutchinson Cancer Research Center |
Methods for inhibiting deacetylase activity
|
WO2003048774A1
(en)
|
2001-12-07 |
2003-06-12 |
Novartis Ag |
Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
|
WO2003053468A1
(en)
|
2001-12-21 |
2003-07-03 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
CA2471957A1
(en)
|
2001-12-28 |
2003-07-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Cyclic tetrapeptide compound and use thereof
|
ITRM20020016A1
(it)
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
CA2473642A1
(en)
|
2002-01-25 |
2003-08-07 |
Sheikh Ismail |
Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy
|
AU2003215112A1
(en)
|
2002-02-07 |
2003-09-02 |
Axys Pharmaceuticals |
Novel bicyclic hydroxamates as inhibitors of histone deacetylase
|
AU2003214055A1
(en)
|
2002-02-08 |
2003-09-02 |
Novartis Ag |
Method for screening for compounds having hdac inhibitory activity
|
EP1482962A4
(en)
|
2002-02-15 |
2009-12-23 |
Sloan Kettering Inst Cancer |
METHOD OF TREATING THIOREDOXIN-MEDIATED DISEASES (TRX)
|
JP4274946B2
(ja)
|
2002-02-20 |
2009-06-10 |
国立大学法人九州工業大学 |
ヒストン脱アセチル化酵素阻害剤およびその製造方法
|
AU2003211362A1
(en)
|
2002-02-21 |
2003-09-09 |
Osaka Industrial Promotion Organization |
N-hydroxycarboxamide derivative
|
BR0308250A
(pt)
*
|
2002-03-04 |
2005-01-11 |
Aton Pharma Inc |
Métodos de indução de diferenciação terminal
|
US20040132825A1
(en)
|
2002-03-04 |
2004-07-08 |
Bacopoulos Nicholas G. |
Methods of treating cancer with HDAC inhibitors
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
US7148257B2
(en)
*
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
EP1497462A4
(en)
|
2002-03-07 |
2007-11-07 |
Univ Johns Hopkins Med |
GENOMIC SCREENING FOR CANCER RELATED GENES DELIVERED EPIGENETICALLY SILENT
|
EP1578924A4
(en)
*
|
2002-03-07 |
2008-08-13 |
Univ Johns Hopkins |
GENOMIC SCREEN ON EPIGENETIC MUTED TUMORSUPPRESSORGENE
|
WO2003076438A1
(en)
|
2002-03-13 |
2003-09-18 |
Janssen Pharmaceutica N.V. |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
|
KR20040090981A
(ko)
|
2002-03-13 |
2004-10-27 |
얀센 파마슈티카 엔.브이. |
신규한 히스톤 디아세틸라제 저해제로서의카보닐아미노-유도체
|
DK1485354T3
(da)
|
2002-03-13 |
2008-09-01 |
Janssen Pharmaceutica Nv |
Sulfonylamino-derivater som nye inhibitorer af histandeacetylase
|
WO2003076422A1
(en)
*
|
2002-03-13 |
2003-09-18 |
Janssen Pharmaceutica N.V. |
Sulfonyl-derivatives as novel inhibitors of histone deacetylase
|
DK1485353T3
(da)
|
2002-03-13 |
2011-11-28 |
Janssen Pharmaceutica Nv |
Nye inhibitorer af histondeacetylase
|
EP1488005A1
(fr)
*
|
2002-03-26 |
2004-12-22 |
Exhonit Therapeutics SA |
Histone deacetylase : nouvelle cible moleculaire de la neurotoxicite
|
AU2003226014A1
(en)
|
2002-03-28 |
2003-10-13 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
US6841565B1
(en)
*
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
US7629343B2
(en)
|
2002-04-03 |
2009-12-08 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
|
AU2003219555A1
(en)
|
2002-04-05 |
2003-10-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Depsipeptide for therapy of kidney cancer
|
TWI319387B
(en)
|
2002-04-05 |
2010-01-11 |
Astrazeneca Ab |
Benzamide derivatives
|
US7495022B2
(en)
|
2002-04-11 |
2009-02-24 |
Sk Chemicals Co., Ltd. |
α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
|
MY134200A
(en)
|
2002-04-12 |
2007-11-30 |
Kowa Co |
Method for treating cancer
|
EP1501489A4
(en)
*
|
2002-04-15 |
2007-11-21 |
Sloan Kettering Inst Cancer |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
|
US6620838B1
(en)
*
|
2002-04-19 |
2003-09-16 |
Signal Pharmaceuticals, Inc. |
Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20030206946A1
(en)
|
2002-04-26 |
2003-11-06 |
Yih-Lin Chung |
Methods for therapy of connective tissue disease
|
GB0209715D0
(en)
|
2002-04-27 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
US20040018522A1
(en)
*
|
2002-05-09 |
2004-01-29 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with multiple sclerosis
|
NO20032183L
(no)
|
2002-05-15 |
2003-11-17 |
Schering Ag |
Histon-deacetylase-inhibitor og anvendelse derav
|
US7351542B2
(en)
*
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
CA2486402C
(en)
*
|
2002-05-22 |
2013-04-30 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
|
CA2486385C
(en)
|
2002-05-22 |
2013-12-10 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
|
US20030224473A1
(en)
|
2002-05-23 |
2003-12-04 |
Mccafferty Dewey G. |
Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
|
EP1506313B1
(en)
|
2002-05-23 |
2011-01-26 |
The Regents of The University of California |
Methods of screening for modulators of the mitochondrial NAD-dependent deacetylase SIRT3
|
US20040002447A1
(en)
*
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
EP1515750B1
(en)
|
2002-06-10 |
2010-08-11 |
Novartis AG |
Combinations comprising epothilones and pharmaceutical uses thereof
|
CA2499709A1
(en)
|
2002-06-19 |
2003-12-31 |
Yoichi Furukawa |
Method for diagnosis of colorectal tumors
|
US20050084967A1
(en)
*
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
JP2005531639A
(ja)
|
2002-07-01 |
2005-10-20 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
Hcvns5bポリメラーゼの阻害剤
|
US20040072770A1
(en)
|
2002-07-03 |
2004-04-15 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-7 and 8
|
SE0202157D0
(sv)
*
|
2002-07-09 |
2002-07-09 |
Biovitrum Ab |
Methods for identification of compounds modulating insulin resistance
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
AU2003253872A1
(en)
|
2002-07-17 |
2004-02-09 |
Chemgenex Pharmaceuticals, Inc. |
Formulations and methods of administration of cephalotaxines, including homoharringtonine
|
MXPA05000555A
(es)
|
2002-07-17 |
2005-04-28 |
Titan Pharmaceuticals Inc |
Combinacion de farmacos quimioterapeuticos para incrementar la actividad antitumoral.
|
DE10233412A1
(de)
|
2002-07-23 |
2004-02-12 |
4Sc Ag |
Neue Verbindungen als Histondeacetylase-Inhibitoren
|
US20050176686A1
(en)
|
2002-07-23 |
2005-08-11 |
4Sc Ag |
Novel compounds as histone deacetylase inhibitors
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
US20080145928A1
(en)
|
2002-07-25 |
2008-06-19 |
Shuki Mizutani |
Factor Taking Part in Transcription Control
|
PL374970A1
(en)
|
2002-08-02 |
2005-11-14 |
Argenta Discovery Limited |
Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
|
CA2495354A1
(en)
|
2002-08-20 |
2004-03-04 |
Yamanouchi Pharmaceutical Co., Ltd. |
An agent for inhibiting articular cartilage extracellular matrix degradation
|
CA2497281A1
(en)
|
2002-08-30 |
2004-03-11 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel depsipeptide compound
|
US20060100140A1
(en)
|
2002-09-13 |
2006-05-11 |
Paul Dent |
Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
|
EP1400806A1
(en)
|
2002-09-18 |
2004-03-24 |
G2M Cancer Drugs AG |
The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
|
US20040127571A1
(en)
|
2002-09-19 |
2004-07-01 |
University Of South Florida |
Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
|
EP1403639A1
(en)
|
2002-09-30 |
2004-03-31 |
G2M Cancer Drugs AG |
Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
|
US20040077084A1
(en)
*
|
2002-10-17 |
2004-04-22 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 4 expression
|
US7282608B2
(en)
|
2002-10-17 |
2007-10-16 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
US20040077083A1
(en)
*
|
2002-10-17 |
2004-04-22 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 4 expression
|
US20060074100A1
(en)
*
|
2002-11-12 |
2006-04-06 |
Klimko Peter G |
Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases
|
AU2003286686B2
(en)
|
2002-11-12 |
2009-07-16 |
Alcon, Inc. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
AU2003295444A1
(en)
|
2002-11-15 |
2004-06-15 |
The Board Of Trustees Of The University Of Illinois |
Methods for in vitro expansion of hematopoietic stem cells
|
GB0226855D0
(en)
|
2002-11-18 |
2002-12-24 |
Queen Mary & Westfield College |
Histone deacetylase inhibitors
|
EP1567142A4
(en)
|
2002-11-20 |
2005-12-14 |
Errant Gene Therapeutics Llc |
TREATMENT OF PULMONARY CELLS WITH HISTONE DEACETYLASE INHIBITORS
|
AU2003296310A1
(en)
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
TW200426138A
(en)
|
2002-12-10 |
2004-12-01 |
Hoffmann La Roche |
Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
|
EP1590318A2
(en)
|
2002-12-12 |
2005-11-02 |
Jawaharlal Nehru Centre For Advanced Scientific Research |
Modulators (inhibitors/activators) of histone acetyltransferases
|
TW200418825A
(en)
|
2002-12-16 |
2004-10-01 |
Hoffmann La Roche |
Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
|
ITMI20022745A1
(it)
|
2002-12-23 |
2004-06-24 |
Coimex Scrl United Companies |
Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
|
WO2004058234A2
(en)
|
2002-12-27 |
2004-07-15 |
Schering Aktiengesellschaft |
Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
|
US20040197888A1
(en)
|
2002-12-31 |
2004-10-07 |
Armour Christopher D. |
Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
|
ITMI20030025A1
(it)
|
2003-01-10 |
2004-07-11 |
Italfarmaco Spa |
Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
EP1583736A1
(en)
|
2003-01-17 |
2005-10-12 |
TopoTarget UK Limited |
Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
|
WO2004067480A2
(en)
|
2003-01-25 |
2004-08-12 |
Oxford Glycosciences (Uk) Ltd |
Substituted phenylurea derivatives as hdac inhibitors
|
TW200424174A
(en)
|
2003-02-06 |
2004-11-16 |
Hoffmann La Roche |
New TP diamide
|
US7208491B2
(en)
|
2003-02-07 |
2007-04-24 |
Hoffmann-La Roche Inc. |
N-monoacylated o-phenylenediamines
|
AU2003900587A0
(en)
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900608A0
(en)
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
WO2004072265A2
(en)
|
2003-02-11 |
2004-08-26 |
Wyeth |
Methods for monitoring drug activities in vivo
|
WO2004071443A2
(en)
|
2003-02-12 |
2004-08-26 |
Irm Llc |
Methods and compositions for modulating stem cells
|
WO2004071464A2
(en)
|
2003-02-12 |
2004-08-26 |
Johns Hopkins University School Of Medicine |
Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
|
US7244751B2
(en)
|
2003-02-14 |
2007-07-17 |
Shenzhen Chipscreen Biosciences Ltd. |
Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
|
MXPA05008904A
(es)
|
2003-02-19 |
2005-10-05 |
Astellas Pharma Inc |
Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
|
EP1599449A2
(en)
|
2003-02-25 |
2005-11-30 |
TopoTarget UK Limited |
Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
|
CA2518318A1
(en)
|
2003-03-17 |
2004-09-30 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
JP2006523693A
(ja)
|
2003-04-01 |
2006-10-19 |
メモリアル スローン−ケタリング キャンサー センター |
ヒドロキサム酸化合物およびその使用方法
|
TW200424187A
(en)
|
2003-04-04 |
2004-11-16 |
Hoffmann La Roche |
New oxime derivatives and their use as pharmaceutically active agents
|
DK1611088T3
(da)
|
2003-04-07 |
2009-10-19 |
Pharmacyclics Inc |
Hydroxymater som terapeutiske midler
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
US20050112128A1
(en)
|
2003-05-21 |
2005-05-26 |
Myogen, Inc. And Board Of Regents, The University Of Texas System |
Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
|
MXPA05012464A
(es)
|
2003-05-21 |
2006-01-30 |
Novartis Ag |
Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
|
PE20050206A1
(es)
|
2003-05-26 |
2005-03-26 |
Schering Ag |
Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
|
US20050020557A1
(en)
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
US7271195B2
(en)
|
2003-06-10 |
2007-09-18 |
Kalypsys, Inc. |
Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
|
CA2528003A1
(en)
|
2003-06-10 |
2004-12-23 |
Kalypsys, Inc. |
Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
|
EP1633751A1
(en)
|
2003-06-16 |
2006-03-15 |
Chroma Therapeutics Limited |
Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
ES2397079T3
(es)
|
2003-06-27 |
2013-03-04 |
Astellas Pharma Inc. |
Agente terapéutico para sarcoma de tejidos blandos
|
JP2007530417A
(ja)
|
2003-07-01 |
2007-11-01 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
細胞及び生物の寿命及びストレス応答を操作するための組成物
|
EP1648459A1
(en)
|
2003-07-02 |
2006-04-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Sir2 regulation
|
EP1644323B1
(en)
|
2003-07-07 |
2015-03-18 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
US7842835B2
(en)
*
|
2003-07-07 |
2010-11-30 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
US7723376B2
(en)
|
2003-07-15 |
2010-05-25 |
Korea Research Institute Of Bioscience And Biotechnology |
2-oxo-heterocyclic compounds and pharmaceutical compositions
|
GB0316889D0
(en)
|
2003-07-18 |
2003-08-20 |
Univ London |
Pharmaceutical agents
|
US20050037992A1
(en)
*
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
WO2005011598A2
(en)
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
WO2005014588A1
(en)
|
2003-08-01 |
2005-02-17 |
Argenta Discovery Limited |
Substituted thienyl-hydroxamic acids having histone deacetylase activity
|
US20050032794A1
(en)
*
|
2003-08-05 |
2005-02-10 |
Padia Janak K. |
Diamine derivatives of quinone and uses thereof
|
WO2005013958A1
(en)
|
2003-08-07 |
2005-02-17 |
Novartis Ag |
Histone deacetylase inhibitors as immunosuppressants
|
CA2533861A1
(en)
|
2003-08-08 |
2005-02-17 |
Novartis Ag |
Combinations comprising staurosporines
|
DE602004004665T2
(de)
|
2003-08-20 |
2008-01-03 |
Pharmacyclics, Inc., Sunnyvale |
Acetylenderivate als inhibitoren von histondeacetylase
|
JP4338734B2
(ja)
|
2003-08-26 |
2009-10-07 |
メルク エイチディーエーシー リサーチ エルエルシー |
Hdac阻害剤による癌処置法
|
EP1667680A4
(en)
|
2003-08-29 |
2008-10-08 |
Aton Pharma Inc |
COMBINED METHODS OF TREATING CANCER
|
US20050059682A1
(en)
*
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
WO2005028620A2
(en)
|
2003-09-16 |
2005-03-31 |
The Rockefeller University |
Histone modifications as binary switches controlling gene expression
|
WO2005025619A1
(en)
|
2003-09-18 |
2005-03-24 |
Novartis Ag |
Combination of a histone deacetylase inhibitor with a death receptor ligand
|
DK1673349T3
(da)
|
2003-09-22 |
2010-10-25 |
S Bio Pte Ltd |
Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
|
CA2539117A1
(en)
|
2003-09-24 |
2005-04-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
PL1670514T3
(pl)
*
|
2003-09-25 |
2010-11-30 |
Astellas Pharma Inc |
Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
|
WO2005034880A2
(en)
|
2003-10-09 |
2005-04-21 |
Aton Pharma, Inc. |
Thiophene and benzothiophene hydroxamic acid derivatives
|
US20050124625A1
(en)
|
2003-10-21 |
2005-06-09 |
Salvati Mark E. |
Piperazine derivatives and their use as modulators of nuclear hormone receptor function
|
CA2543570A1
(en)
|
2003-10-27 |
2005-05-06 |
S*Bio Pte Ltd |
Acylurea connected and sulfonylurea connected hydroxamates
|
TW200524575A
(en)
|
2003-10-27 |
2005-08-01 |
S Bio Pte Ltd |
Biaryl linked hydroxamates: preparation and pharmaceutical applications
|
IN2003CH00929A
(no)
|
2003-11-13 |
2008-10-06 |
|
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
EP1694329A4
(en)
|
2003-11-26 |
2009-06-03 |
Aton Pharma Inc |
DIAMOND AND IMINODIACETIC ACID HYDROXAMINIC DERIVATIVES
|
WO2005051901A1
(en)
|
2003-11-28 |
2005-06-09 |
The University Of Queensland |
Anti-cancer agents
|
JP5107579B2
(ja)
|
2003-12-02 |
2012-12-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
新規の種類のヒストン脱アセチル化酵素阻害剤としてのZn2+キレートモチーフ係留短鎖脂肪酸
|
WO2005058298A2
(en)
|
2003-12-10 |
2005-06-30 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
EP1541549A1
(en)
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
US8652502B2
(en)
|
2003-12-19 |
2014-02-18 |
Cordis Corporation |
Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
|
WO2005065681A1
(en)
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
|
WO2005066151A2
(en)
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
JP2007527418A
(ja)
|
2003-12-29 |
2007-09-27 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
肥満及びインシュリン耐性障害を治療又は防止するための組成物
|
EP1709176A1
(en)
|
2004-01-21 |
2006-10-11 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
|
WO2005092899A1
(en)
|
2004-03-26 |
2005-10-06 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
US7253204B2
(en)
*
|
2004-03-26 |
2007-08-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|